Friday, June 2, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

RFI – Manufacturing Autoinjectors for Nerve Agent Countermeasures

by Global Biodefense Staff
October 21, 2013

Medical Countermeasure Systems-Chemical Defense Pharmaceuticals (MCS-CDP) Joint Product Management Office is conducting market research for manufacturing capability for the nerve agent antidotes atropine and 2-pralidoxime, in a single autoinjector for intramuscular administration by the U.S. military.

The DoD currently procures the nerve agent antidotes atropine and 2-pralidoxime as components of the Antidote Treatment Nerve Agent Autoinjector (ATNAA), the replacement for the two injector MARK-1 nerve agent antidote kits. The ATNAA is a self-contained unit designed for self- or buddy-administration by military personnel.

Currently, MCS-CDP is seeking capabilities from potential sources for development of an autoinjector drug-delivery device that will simultaneously or sequentially deliver the nerve agent antidotes atropine and 2-PAM. These life-saving antidotes are used in conjunction with the pretreatment, pyridostigmine bromide (PB), and an anticonvulsant.

The delivery device platform and antidotes must be stable at operationally relevant temperatures to include temperature extremes experienced by service members in the field. The storage conditions and shelf life must be equal to standards of the current ATNAA and be administrable by self- and buddy-aid in Mission Oriented Protective Posture 4 (MOPP-4) gear.

As such, MCS-CDP is seeking information on current industry capabilities from interested entities. Further details are available under Solicitation Number: W911QY-14-S-CDP1. The response deadline is November 4, 2013.

Tags: JPEO-CBRNDRFI

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC